

BRIDGE FUNDING AWARD in ovarian cancer research
\$30,000 Six-Month Award
Request for Applications
Release Date: March 11, 2022



Bridge Funding Award Overview:

The Rivkin Center is announcing funds for one Bridge Funding Award based on scientific merit. The purpose of Bridge Funding is to allow researchers to produce data needed to substantiate their proposal resubmission to federal funding agencies for a promising new research project. The Rivkin Center provides interim funding of up to \$30,000 to researchers who have submitted an R01, R21, K08, K23, or K99 proposal to the National Institutes of Health (NIH) or an original proposal to the Department of Defense (DoD) pertaining to ovarian cancer and who have not received, but were close to, a fundable score. Investigator-initiated projects in all areas of ovarian cancer research are eligible. Special consideration will be given to research that has clinical applicability. *Funds are for direct costs only; institutional overhead and indirect costs will not be included in the award.*

Applicants may budget for salary support, materials, supplies, consumables, and other expenses as justified. Budget and budget justification must be included with the application.

Eligibility:

Investigators at all levels are encouraged to apply. Unfunded first submission NIH R01, R21, K08, K23, and K99 proposals (no A1 or A2 proposals) as well as original DoD proposals are eligible for consideration. NIH proposals must have scored in the 20th percentile or lower, and DoD proposals must have scored 2.0 or less. Proposals must have received their agency score within the past 9 months. Proposals must require at least six months of additional research work prior to resubmission.

Requirements upon funding:

A final scientific report, final financial report, and lay abstract must be provided within 90 days after the completion of the funding period. The outcome of the resubmission must also be reported to the Rivkin Center.

Application Format and Instructions:

Applicants should submit a proposal application to the Rivkin Center via proposalCENTRAL including applicant/PI and institution contact information, scientific proposal summary, budget information, a copy of the original proposal to NIH or DoD, a copy of the reviewers' Summary Statement evaluating the proposal submitted to NIH or DoD together with responses to the Statement's critiques. Additional materials (e.g. published papers, letters of support) will not be considered. The scientific proposal summary should include three components: (A) Abstract describing the rationale, specific aims, and general methodology of the project (not more than one page); (B) Explanation of the potential impact of this research on the understanding, prevention, diagnosis, and/or treatment of ovarian cancer (one half page to one page in length); (C) Discussion of how the funds from the Rivkin Center will be used to address the score-driving issues raised in the Summary Statement from the reviewers (one half page to one page in length). Be sure to include the expected date of resubmission to NIH or of new submission to DoD.

Application Submission:

All application materials should be submitted through [proposalCENTRAL](#) by the **application due date (May 2, 2022, 5PM Eastern Time)**. Applicants who do not already have an account in proposalCENTRAL must register for an account prior to beginning application. Once completed, the application must be validated to ensure all materials have been submitted. Electronic signatures are acceptable on the signature page.

More Information:

Visit [proposalCENTRAL.com](#) or [www.rivkin.org](#) for the full "Bridge Funding Award Guidelines." Questions may be directed to Jackie.Lang@rivkin.org or (206) 584-2357.

The Rivkin Center for Ovarian Cancer is an independent 501(c)(3) non-profit organization established in Seattle in 1996 by medical oncologist Saul E. Rivkin MD (retired), in loving memory of his wife Marsha, who lost her life to ovarian cancer. The Rivkin Center invests in cutting-edge research to prevent, detect, and cure ovarian cancer, a deadly and under-funded disease. The Rivkin Center has funded over \$14 million in research grants worldwide. For more information, please visit [www.rivkin.org](#) or call (206)490-0847.